Abstract
Recent interest in commercial devices containing germicidal ultraviolet lamps with a peak emission wavelength at 222 nm (GUV222) has focused on mitigating virus transmission indoors and disinfecting indoor spaces while posing minimum risk to human tissue. However, 222 nm light can produce ozone (O3) in air. O3 is an undesirable component of indoor air because of health impacts from acute to chronic exposure and its ability to degrade indoor air quality through oxidation chemistry. We measured the total irradiance of one GUV222 lamp at a distance of 5 cm away from the source to be 27.0 W m-2 ± 4.6 W m-2 in the spectral range of 210 nm to 230 nm, with peak emission centered at 222 nm and evaluated the potential for the lamp to generate O3 in a 31.5 m3 stainless steel chamber. In seven four-hour experiments average O3 mixing ratios increased from levels near the detection limit of the instrument to 48 ppbv ± 1 ppbv (94 μg m-3 ± 2 μg m-3). We determined an average constant O3 generation rate for this lamp to be 1.10 mg h-1 ± 0.15 mg h-1. Using a radiometric method and chemical actinometry, we estimate effective lamp fluences that allow prediction of O3 generation by the GUV222 lamp, at best, within 10 % of the measured mixing ratios. Because O3 can react with gases and surfaces indoors leading to the formation of other potential by-products, future studies should evaluate the production of O3 from GUV222 air cleaning devices.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript.
